FibroBiologics (FBLG) Maxim Group’s 2024 Healthcare Virtual Summit summary

Scientific and technological innovation

• Focus on fibroblasts as a novel cell therapy platform, highlighting their abundance, robustness, and superior therapeutic potency compared to stem cells.

• Fibroblasts are involved in wound healing and immune modulation, with 16 identified subtypes used for targeted clinical indications.

• No genetic modification is required for initial indications, but intellectual property covers potential modifications.

• Preclinical data show fibroblasts outperform stem cells in immune modulation and are easier and more economical to culture.

• Extensive patent portfolio with over 160 patents, including organoid and spheroid formulations for broader applications.

Clinical development and pipeline

• Diabetic foot ulcer is the lead indication, with a 12-week clinical trial planned for 2025 and primary outcomes expected by year-end.

• IND approved for degenerative disc disease; phase I safety trial completed for multiple sclerosis, with no adverse events and no MS attacks in five patients over six months.

• Preclinical studies in multiple sclerosis show immune modulation, remyelination, and microglia control.

• Plans to seek partners for larger, more expensive trials, especially in multiple sclerosis.

• Preclinical data in degenerative disc disease show tissue rebuilding and inflammation reduction, with easy differentiation into chondrocyte-like cells.

Market positioning and regulatory environment

• Fibroblast therapy targets chronic wound care as a significant near-term opportunity, aiming for higher quality and lower recurrence rates than current treatments.

• FDA is increasingly supportive of cell-based therapies, creating a favorable environment for accelerated development and approval.

• Platform technology enables expansion into various indications, including diabetes, autoimmune disorders, and tissue regeneration.

• Organoid innovations include pancreatic, thymic, and bone marrow organoids, broadening therapeutic potential.

• Upcoming presentations at BIO-Europe in November and Biotech Showcase in January to increase visibility.